GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Operating Margin %
中文

Genocea Biosciences (Genocea Biosciences) Operating Margin % : -5,841.85% (As of Mar. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Genocea Biosciences's Operating Income for the three months ended in Mar. 2022 was $-15.77 Mil. Genocea Biosciences's Revenue for the three months ended in Mar. 2022 was $0.27 Mil. Therefore, Genocea Biosciences's Operating Margin % for the quarter that ended in Mar. 2022 was -5,841.85%.

The historical rank and industry rank for Genocea Biosciences's Operating Margin % or its related term are showing as below:


GNCAQ's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.8
* Ranked among companies with meaningful Operating Margin % only.

Genocea Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Genocea Biosciences's Operating Income for the three months ended in Mar. 2022 was $-15.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-55.44 Mil.


Genocea Biosciences Operating Margin % Historical Data

The historical data trend for Genocea Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Operating Margin % Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -3,457.62 -3,174.47

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -713.95 - -5,841.85

Competitive Comparison of Genocea Biosciences's Operating Margin %

For the Biotechnology subindustry, Genocea Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genocea Biosciences's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Operating Margin % falls into.



Genocea Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genocea Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-52.093 / 1.641
=-3,174.47 %

Genocea Biosciences's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=-15.773 / 0.27
=-5,841.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences  (OTCPK:GNCAQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genocea Biosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences (Genocea Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber director 2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell 10 percent owner
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner officer: VP of Research C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815

Genocea Biosciences (Genocea Biosciences) Headlines

From GuruFocus

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 05-24-2022

Genocea to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 01-05-2022

Genocea to Present at Upcoming Conferences

By Marketwired Marketwired 09-28-2021

Genocea to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 01-05-2022